How to Get Dayvigo (Lemborexant) in Wyoming

What Is Dayvigo and How Does It Work?

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist (DORA) that blocks both OX1R and OX2R signaling to quiet the wake-promoting pathway rather than broadly suppressing the central nervous system. The FDA approved lemborexant in December 2019 for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both [1]. The approved doses are 5 mg and 10 mg taken no more than once per night, immediately before bed, with at least 7 hours remaining before planned awakening.

Orexin (also called hypocretin) is a neuropeptide that drives wakefulness [2]. In people with chronic insomnia, orexin tone is often excessive at night. Lemborexant competitively blocks both orexin receptor subtypes, selectively dampening arousal without the same risk of residual morning sedation seen with GABA-modulating agents like zolpidem [3]. Its half-life of roughly 17 to 19 hours is longer than the older DORA suvorexant, which drives the once-nightly dosing schedule and means patients should avoid operating heavy machinery the morning after taking 10 mg [1].

In SUNRISE-1 (N=291, JAMA Netw Open 2019), both the 5 mg dose and 10 mg dose of lemborexant significantly outperformed placebo on polysomnography-measured subjective sleep onset: the 10 mg arm reduced latency to persistent sleep by 22.2 minutes versus 10.7 minutes for placebo at month 1 (P<0.001) [4]. Wake after sleep onset was also reduced by 40.7 minutes in the 10 mg arm versus 17.8 minutes for placebo across the first month of treatment [4].

SUNRISE-2 (N=949, Sleep 2020) evaluated lemborexant over 12 months and found sustained efficacy with no evidence of rebound insomnia or withdrawal on discontinuation, distinguishing it from benzodiazepine receptor agonists [5]. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline states: "We suggest the use of lemborexant for sleep onset and sleep maintenance insomnia in adults" as one of only a handful of agents receiving a conditional recommendation based on moderate-quality evidence [6].

Is Lemborexant a Controlled Substance? What Wyoming Providers Need to Know

Lemborexant is a Schedule IV controlled substance under the DEA Controlled Substances Act [1]. That classification places it in the same tier as benzodiazepines and zolpidem, which has practical consequences for Wyoming patients.

Schedule IV status means:

• A prescriber must hold an active DEA registration.
• Wyoming state law (Wyoming Controlled Substances Act, W.S. 35-7-1001 et seq.) requires controlled substance prescriptions to comply with state board rules in addition to federal DEA requirements [7].
• Telehealth prescribing of Schedule IV substances became substantially easier after the DEA's May 2023 telemedicine special registration framework and the subsequent temporary extension allowing audio-video consultations to count toward the prescribing standard through at least December 2025 [8].

Prescribers in Wyoming must maintain a valid Wyoming Controlled Substance License in addition to their DEA number [7]. Out-of-state telehealth providers writing Schedule IV prescriptions for Wyoming patients must hold Wyoming licensure or qualify under an interstate compact such as the Interstate Medical Licensure Compact (IMLC), to which Wyoming is a member state [9].

The maximum supply per prescription for Schedule IV in Wyoming follows federal rules: no more than a 90-day supply, no refills beyond 5 times within 6 months of the original prescription date [7].

How to Get a Dayvigo Prescription in Wyoming: Step-by-Step

Getting lemborexant in Wyoming follows a clear path whether you go through a local clinic or a telehealth service.

Step 1. Choose your prescribing route. In-person visits to a Wyoming-licensed physician, nurse practitioner, or physician assistant work, but telemedicine is available statewide and reaches patients in rural areas such as Lander, Pinedale, or Thermopolis where in-person sleep specialists are scarce [9].

Step 2. Complete a structured sleep assessment. A provider evaluating you for Dayvigo will typically use the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI), review your sleep diary or actigraphy data if available, and screen for comorbid sleep apnea [6]. The AASM guideline specifies that obstructive sleep apnea should be assessed before prescribing any DORA because lemborexant may worsen respiratory drive in patients with moderate-to-severe OSA [6].

Step 3. Review labs and contraindications. No routine bloodwork is required before initiating lemborexant in most healthy adults, but providers typically check a basic metabolic panel if hepatic impairment is suspected, because lemborexant is primarily metabolized by CYP3A4 and plasma levels can rise substantially with moderate or strong CYP3A4 inhibitors such as fluconazole or clarithromycin [1]. Dayvigo is contraindicated in patients with narcolepsy [1].

Step 4. Receive your e-prescription. Once the prescriber approves the plan, a Schedule IV e-prescription is transmitted directly to your chosen pharmacy. Wyoming law accepts electronic prescriptions for controlled substances (EPCS) that comply with DEA 21 CFR Part 1311 [7].

Step 5. Fill at a local or mail-order pharmacy. Any retail pharmacy in Wyoming (Walgreens, Smith's, Walmart, independent pharmacies) can dispense lemborexant. Patients without adequate commercial coverage may also use mail-order pharmacies licensed to ship to Wyoming. GoodRx and similar discount programs can reduce the cash price of a 30-tablet supply to approximately $300 to $370 depending on the dose [10].

Step 6. Follow up at 4 weeks. The prescribing provider should reassess sleep quality and any next-morning impairment at the 4-week mark; AASM guidance recommends treatment be re-evaluated at least every 3 months for chronic insomnia pharmacotherapy [6].

Telehealth Prescribing of Dayvigo in Wyoming

Wyoming permits telehealth prescribing for controlled substances when the provider meets licensure requirements and the clinical standard of care. The Wyoming Telehealth Act (W.S. 33-26-102) defines telehealth broadly enough to include synchronous audio-video encounters as equivalent to in-person visits for prescribing purposes, provided the provider establishes a valid patient-provider relationship [9].

For a telehealth platform to prescribe lemborexant to a Wyoming resident, the platform must:

1. Employ or contract with a prescriber holding an active Wyoming license.
2. Use a real-time, two-way audio-video connection that allows the provider to evaluate the patient.
3. Maintain records compliant with Wyoming Board of Medicine regulations and DEA electronic prescribing standards [7][9].

The Ryan Haight Online Pharmacy Consumer Protection Act historically required at least one in-person visit before a controlled substance could be prescribed via telemedicine. The DEA's 2023 telemedicine special registration proposed rule and its subsequent enforcement discretion policy have allowed audio-video consultations to substitute for in-person visits for Schedule III through V substances through the end of 2025 [8]. Patients should confirm with their telehealth provider that the platform complies with the current DEA policy at the time of their consultation.

Telehealth services that hold Wyoming licensure and specialize in sleep or behavioral health can conduct a 20 to 30-minute intake, order any needed labs electronically, and transmit the e-prescription on the same day in many cases. Rural Wyoming residents with spotty broadband can sometimes complete the visit via synchronous audio-only if their provider documents medical necessity for the audio-only format, consistent with CMS guidance extended through 2025 [8].

Wyoming Medicaid, Insurance, and Cost Considerations

Wyoming Medicaid does not cover Dayvigo (lemborexant) as of July 2025. Patients enrolled in Wyoming Medicaid who need pharmacological treatment for insomnia will typically be offered a generic alternative such as trazodone, doxepin 3 mg or 6 mg, or zolpidem tartrate, all of which appear on the Wyoming Medicaid preferred drug list [11].

Commercial insurance coverage varies. Medicare Part D plans cover lemborexant at different tier levels; as of 2024 CMS data, approximately 63% of Part D formularies include lemborexant at Tier 3 or Tier 4, meaning a 30-day supply may cost $45 to $150 after deductible with mid-tier commercial plans [12]. Patients should run a formulary check with their specific plan.

Eisai offers a patient savings program for commercially insured patients: eligible patients may pay as little as $15 per month through the Dayvigo co-pay card, available at the manufacturer's website [10]. Uninsured patients paying full cash price at major Wyoming chains average $340 for 30 tablets of the 10 mg dose; manufacturer coupons and GoodRx codes can reduce this to approximately $290 to $310 [10].

No generic lemborexant is currently available. The earliest possible generic entry date based on Eisai's U.S. patent portfolio is estimated to be after 2035 [13].

503A Compounding of Lemborexant in Wyoming

Wyoming-licensed 503A compounding pharmacies may prepare customized lemborexant formulations for individual patients upon receipt of a valid prescription from a licensed Wyoming provider. This pathway is relevant for patients who need a non-standard dose strength, a specific excipient-free formulation because of allergies, or an alternative delivery form evaluated by their prescriber [14].

503A pharmacies must comply with Wyoming State Board of Pharmacy rules and USP <795> and <797> standards where applicable [14]. Lemborexant is not on the FDA's list of bulk drug substances approved for 503A compounding, which means a compounding pharmacy must use an FDA-approved finished dosage form as the starting point or document a specific patient need under state law [15]. Patients should confirm with both their prescriber and the compounding pharmacy that the preparation meets Wyoming Board of Pharmacy requirements before ordering.

503A pharmacies in Wyoming may ship within state lines to patients. Interstate shipment of compounded controlled substances carries additional federal scrutiny; any 503A pharmacy shipping lemborexant preparations across state lines must comply with both the originating and receiving state's pharmacy board rules and applicable DEA regulations [15].

Who Can Prescribe Dayvigo in Wyoming?

Any Wyoming-licensed prescriber with an active DEA registration and Wyoming Controlled Substance License may write a lemborexant prescription. That includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) licensed by the Wyoming Board of Medicine [9].
• Nurse practitioners (NP) practicing under a full-practice authority model. Wyoming granted NPs full practice authority in 2013, meaning NPs may prescribe Schedule IV controlled substances independently without a physician collaborating agreement [16].
• Physician assistants (PA) licensed by the Wyoming Board of Medicine. Wyoming PAs hold prescriptive authority for Schedule IV substances with a supervising physician agreement on file [9].
• Psychiatrists and sleep medicine specialists, who are the most common specialists prescribing DORAs but are not required for initial prescribing.

Dentists and optometrists in Wyoming do not hold Schedule IV prescribing authority relevant to insomnia pharmacotherapy.

Prior Authorization Requirements for Dayvigo in Wyoming

Commercial insurers in Wyoming that cover Dayvigo frequently require prior authorization (PA). The documentation package a prescriber typically needs to submit includes:

• An insomnia diagnosis coded to ICD-10-CM G47.00 (insomnia, unspecified) or a more specific subtype.
• Documentation of at least one trial and failure of a generic first-line agent, most commonly zolpidem tartrate or trazodone, with duration of trial (usually 30 days minimum) [6].
• Objective or subjective sleep impairment data such as ISI scores or sleep diary entries.
• Attestation that obstructive sleep apnea has been ruled out or is being treated [6].

Most commercial PA decisions in Wyoming take 2 to 5 business days. Urgent PA (same-day or next-business-day) is available when a provider documents clinical urgency. If PA is denied, the prescriber may request a peer-to-peer review with the plan's medical director, citing SUNRISE-1 polysomnography data and AASM guideline language [4][6].

Wyoming has a standardized prior authorization form under Wyoming statute that commercial insurers must accept; providers can reference W.S. 26-40-109 when submitting PA documentation to avoid insurer-specific form delays [17].

How Long Does It Take to Get Dayvigo in Wyoming?

The timeline depends on the prescribing route and insurance status.

Cash-pay, telehealth route. A same-day or next-day telehealth consultation followed by e-prescription to a local Wyoming pharmacy means most patients can pick up lemborexant within 24 to 48 hours of completing their intake. Mail-order fulfillment adds 3 to 5 business days for standard shipping to Wyoming addresses.

Insurance-covered route with prior authorization. Add 2 to 5 business days for PA processing after the clinical visit. Total time from initial consultation to first dose is typically 5 to 10 business days in Wyoming.

In-person specialty referral route. Sleep medicine specialists in Wyoming operate primarily out of Casper (Wyoming Medical Center Sleep Center) and Cheyenne (Cheyenne Regional Medical Center). New patient wait times at these facilities range from 4 to 12 weeks, making telehealth the faster path for uncomplicated chronic insomnia cases [9].

Once the prescription is filled, lemborexant is taken at 5 mg initially and may be increased to 10 mg by the prescriber if the lower dose is insufficient after at least 7 days. Most patients notice meaningful improvement in sleep onset within the first week; SUNRISE-1 showed significant polysomnographic improvement by night 1 at both dose levels [4].

Safety, Side Effects, and Morning-Impairment Risk

Lemborexant's most clinically significant adverse effect is next-morning somnolence, reported in approximately 10% of patients taking 10 mg in SUNRISE-1 [4]. The FDA label includes a warning that patients should not drive or operate heavy machinery the morning after taking 10 mg until they know how the drug affects them [1]. The 5 mg dose showed a lower rate of next-morning impairment, approximately 6%, in the same trial [4].

Complex sleep behaviors, including sleepwalking and sleep driving, have been reported with all sedative-hypnotics. The FDA issued a black-box warning covering this class in 2019 [1]. Patients with a personal or family history of parasomnia should discuss this risk specifically with their prescriber before starting lemborexant.

Drug interactions worth noting: strong CYP3A4 inhibitors such as ketoconazole can increase lemborexant AUC by approximately 4-fold; concomitant use is contraindicated [1]. Moderate CYP3A4 inhibitors such as fluconazole increase AUC roughly 2-fold, and the label recommends limiting the dose to 5 mg in those cases [1]. CNS depressants including alcohol, opioids, and benzodiazepines increase sedation risk additively [1].

Lemborexant shows no evidence of physical dependence, tolerance, or withdrawal in trials up to 12 months, consistent with its non-GABA mechanism, and SUNRISE-2 confirmed no rebound insomnia after abrupt discontinuation [5]. This pharmacological profile makes it a preferred option for patients with a history of substance use disorder where benzodiazepine receptor agonists carry greater risk.